{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG000","lowerLimit":"12.5","upperLimit":"NA","value":"24.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Time from the date of first dose of study treatment to the date of first documented disease progression as per investigator assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"}],"paramType":"MEDIAN","populationDescription":"All participants on the HGG cohort to whom study treatment had been assigned and who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approx. 4.8 years","title":"HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Investigatort Assessment Using RANO Criteria","type":"SECONDARY","unitOfMeasure":"Months"}